<DOC>
	<DOC>NCT00560560</DOC>
	<brief_summary>This study will test if there is any survival benefit in patients with refractory metastatic colorectal cancer that receive CP-751, 871.</brief_summary>
	<brief_title>Study Using CP-751,871 In Patients With Stage IV Colorectal Cancer That Has Not Responded To Previous Anti-Cancer Treatments</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Patients who have stage IV colorectal cancer Patients whose disease has worsened despite prior anticancer therapy Patients who have satisfactory bonemarrow, kidney and liver function Patients who are being simultaneously treated with another anticancer therapy. Patients who have previously received anticancer therapy that works like CP751, 871 (targets insulinlike growth factor receptor) Patients that are pregnant or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Refractory Colorectal</keyword>
	<keyword>Single arm</keyword>
	<keyword>Phase 2</keyword>
</DOC>